Erectile dysfunction: a global review of intracavernosal injectables

Duncan, Catriona; Omran, Ghadir J; Teh, Jiasian; Davis, Niall F.; Bolton, Damien; Lawrentschuk, Nathan

doi:10.1007/s00345-019-02727-5

Cited by 21 publications

(17 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the PDU following intracavernosal vasoactive agent injection in the patient examined for ED, peak systolic blood flow rate over 30 cm/s in both cavernosal arteries shows normal arterial system, whereas end-diastolic blood flow rate below 3 cm/s demonstrates the presence of normal venous function. Vascular ED should be considered in the presence of abnormal findings (Sikka et al, 2013 Alprostadil, papaverine and phentolamine are agents which can be used for this aim (Duncan et al, 2019).…”

Section: Discussionmentioning

confidence: 99%

Efficiency of intracavernosal alprostadil and oral clomiphene citrate combination treatment in penile vasculogenic erectile dysfunction patients accompanied by late‐onset hypogonadism

et al. 2020

View full text Add to dashboard Cite

Erectile dysfunction (ED) refers to difficulty in starting and maintaining an adequate erection for satisfactory sexual performance and the stability of this condition (Burnett et al., 2018). The estimated prevalence of ED in men > 40 years of age is almost 50% (Bella, Lee, Carrier, Benard, & Brock, 2015). Different therapeutic agents have been developed for ED treatment, and their effect mechanism depends on the understanding of erection physiology. In ED treatment-resistant patients, lifestyle changes as a first-line treatment option and phosphodiesterase type 5 inhibitors (PDE5 inhibitors) as a second-line treatment option are used. PDE-5 inhibitors are noninvasive, generally well tolerated and efficient in most males. Intracavernosal injections (ICUs), such as alprostadil and papaverine, can be used in 25%-50% of patients who are irresponsive to the treatment and who contraindicate PDE5 inhibitors (Bella et al., 2015; Hatzimouratidis et al., 2019).

show abstract

Section: Discussionmentioning

confidence: 99%

Efficiency of intracavernosal alprostadil and oral clomiphene citrate combination treatment in penile vasculogenic erectile dysfunction patients accompanied by late‐onset hypogonadism

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Aviptadil, a combination of synthetic vasoactive intestinal polypeptide (VIP) (~28 amino acids) and phentolamine, is approved in Europe for the treatment of erectile dysfunction [ 51 ]. The VIP is a neuropeptide mostly present in the lungs and nasal mucosa.…”

Section: Clinical Approachesmentioning

confidence: 99%

Emerging Therapeutic Modalities against COVID-19

et al. 2020

View full text Add to dashboard Cite

The novel SARS-CoV-2 virus has quickly spread worldwide, bringing the whole world as well as the economy to a standstill. As the world is struggling to minimize the transmission of this devastating disease, several strategies are being actively deployed to develop therapeutic interventions. Pharmaceutical companies and academic researchers are relentlessly working to investigate experimental, repurposed or FDA-approved drugs on a compassionate basis and novel biologics for SARS-CoV-2 prophylaxis and treatment. Presently, a tremendous surge of COVID-19 clinical trials are advancing through different stages. Among currently registered clinical efforts, ~86% are centered on testing small molecules or antibodies either alone or in combination with immunomodulators. The rest ~14% of clinical efforts are aimed at evaluating vaccines and convalescent plasma-based therapies to mitigate the disease's symptoms. This review provides a comprehensive overview of current therapeutic modalities being evaluated against SARS-CoV-2 virus in clinical trials.

show abstract

“…By inhibiting type 5 phosphodiesterase (PDE), sildenafil (Viagra®) increases the level of cyclic guanosine monophosphate (cGMP) and induces vasodilatory effects in the pulmonary vasculature. Thus, it has FDA approval for the treatment of pulmonary arterial hypertension (PAH) in adults [278,279].…”

Section: Sildenafilmentioning

confidence: 99%

Pharmacological treatments of COVID-19

et al. 2020

View full text Add to dashboard Cite

The viral infection due to the new coronavirus or coronavirus disease 2019 (COVID-19), which was reported for the first time in December 2019, was named by the World Health Organization (WHO) as Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV2), because of the very similar genome and also its related symptoms to SARS-CoV1. The ongoing COVID-19 pandemic with significant mortality, morbidity, and socioeconomic impact is considered by the WHO as a global public health emergency. Since there is no specific treatment available for SARS-CoV2 infection, and or COVID-19, several clinical and sub-clinical studies are currently undertaken to find a gold-standard therapeutic regimen with high efficacy and low side effect. Based on the published scientific evidence published to date, we summarized herein the effects of different potential therapies and up-to-date clinical trials. The review is intended to help readers aware of potentially effective COVID-19 treatment and provide useful references for future studies.

show abstract

Erectile dysfunction: a global review of intracavernosal injectables

Cited by 21 publications

References 14 publications

Efficiency of intracavernosal alprostadil and oral clomiphene citrate combination treatment in penile vasculogenic erectile dysfunction patients accompanied by late‐onset hypogonadism

Efficiency of intracavernosal alprostadil and oral clomiphene citrate combination treatment in penile vasculogenic erectile dysfunction patients accompanied by late‐onset hypogonadism

Emerging Therapeutic Modalities against COVID-19

Pharmacological treatments of COVID-19

Contact Info

Product

Resources

About